You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

439 Results
Document
May 2024
Document
Aug 2024
Document
Aug 2024
Document
Aug 2024
Document
Aug 2024
Document
Oct 2024
Document
Oct 2024
Document
New
Nov 2024
Document
New
Nov 2024
Guidelines and Advice
Status: Current
ID: GL END 7-24
Updated
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
olaparib,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-2
Updated
Nov 2024

Pages